Company intelligence / Profile preview

IRBM

Pomezia, Lazio, Italyirbm.com ↗

Ownership: Private
Employees: ~250
Development stage: Commercial

Overview

IRBM has a strong track record of delivering preclinical candidates that have progressed into clinical testing, with more than four drugs currently marketed that they contributed to discovering. They recently disclosed novel preclinical agents showing strong antitumor efficacy against aggressive brain tumors and acute lymphoblastic leukemia at AACR meetings in early 2024.

Therapeutic areas: OncologyNeurologyInfectious Diseases
Modalities: Small moleculesPeptidesAntibodiesExperimental adenoviral vaccines
Industry: Biotech

Drug pipeline

5 assets

3-cyclohexyl-1-(2-morpholin-4-yl-2-oxoethyl)-2-phenyl-1H-indole-6-carboxylic acid

Preclinical

4 more assets in the full pipeline.

Request access →

Partnerships

Collaborations with pharmaceutical companiesbiotech firmspartnerships span pharma, biotech, non-profit foundations

Beyond the preview

Go deeper on IRBM.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IRBM.

Explore the full profile